Dr. Ghosh on Efficacy Results from the Phase 2 PILOT trial in Non-Hodgkin Lymphoma

Nilanjan Ghosh, MD, PhD, director, Lymphoma Program, physician, Levine Cancer Institute, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.

At a median follow-up of 5 months, 24 patients (89%) had achieved an objective response, says Ghosh.

​Moreover, the complete response ​(CR) rate was 56%, and 10 of 12 patients who achieved a CR with at least 1 follow-up assessment remained in CR, ​says Ghosh.

Additionally, 33% of patients had a partial response. Of these patients, 2 converted into a CR, Ghosh explains. The estimated 3- and 6-month CR rates were 63% and 53%.